Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
BD
01/31/2012
RED RED
Solution now available to help healthcare workers reduce the risk of needlestick injury and blood exposure from short peripheral IV catheter insertion
Insyte Autoguard
BD launches new InsyteTM AutoguardTM BC with Blood Control Technology
 
(January 2011) - BD (Becton, Dickinson and Company), a leading global medical technology company, announced the launch of a new safety-engineered IV catheter, the BD InsyteTM Autoguard TM BC with Blood Control Technology, which reduces the risk of blood exposure by 95 per cent .

EU Directive (Council Directive 2010/32/EU ) was developed to help prevent healthcare workers from sustaining injuries from medical sharps, such as peripheral IV catheters and blood collection devices, which can lead to infection with blood-borne pathogens, including hepatitis and HIV. The Directive, and early implementation guidance from key institutions, specifically cites the use of “safety-engineered” medical devices as a key prevention measure.

In addition to the risk of needlestick injury, healthcare professionals are also at daily risk of blood and bodily fluid exposures. An EPINETAC study conducted a few years ago found that eight percent of exposures in Spain were mucocutaneous (mucosal contamination of broken or intact skin) , and in a more recent report on biological accidents in Madrid 13 percent of reported exposures were found to be mucocutaneous . The number of mucocutaneous exposures may be less than percutaneous injuries (cuts or punctures with sharps), but they still represent a significant risk. According to another recently published study on underreporting of blood and bodily fluid exposures, only 67 per cent of sharps injuries were reported and only 17.1 per cent of mucocutaneous blood exposures were reported .

“BD is making safety safer with this new generation of IV catheter technology, which helps to protect healthcare workers from both needlestick injury and blood exposure risks,” said Greg Walsh, Vice President and General Manager, BD.

In a clinical study, the BD Insyte™ Autoguard™ BC reduced the risk of blood exposure by 95 per cent when compared to a standard non-blood-control IV catheter . Due to the fact that there is dramatically less blood leakage, and therefore less blood getting onto gloves, clothing, shoes, bedding, floors or equipment, BD Insyte™ Autoguard™ BC can also result in a lower incidence of cross-contamination. This new design provides healthcare workers with reassurance that they are using a device that helps make safety safer for both themselves and their patients’ environment.

The BD Insyte™ Autoguard™ BC is the latest in BD’s portfolio of innovative safety-engineered products designed to help minimise the risks to healthcare workers of exposure to blood-borne pathogens.

 
 
Related links:
 
 
Permalink: http://www.mercadosbiotecnologicos.com/?iid=53&own=2&itid=1&lan=en
 
Search